Anti-CD19/BCMA Universal Chimeric Antigen Receptor T Cells therapy (Rui Therapeutics)

N/A

Report date: 2026/02/26 20:00:22

Base Information

Drug NameAnti-CD19/BCMA Universal Chimeric Antigen Receptor T Cells therapy (Rui Therapeutics)
Drug Alias NameKN3601KN-3601
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsB-cell maturation protein modulatorsT lymphocyte replacements
TargetsB-lymphocyte antigen CD19B-cell maturation protein
Therapy Area/IndicationsAutoimmune DiseasesScleroderma, SystemicLupus Erythematosus, Systemic +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShenzhen Rui Therapeutics Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShenzhen Rui Therapeutics Co Ltd
Inactive CompaniesN/A
Active IndicationsAutoimmune DiseasesScleroderma, SystemicLupus Erythematosus, Systemic +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A